Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses
This article was originally published in PharmAsia News
Executive Summary
Japan's second-largest drug maker Astellas estimates net profit is down by 27 percent to ¥125 billion ($1.375 billion) for fiscal year 2009, due largely to decreasing sales from patent losses in major products Prograf (tacrolimus) and Flomax (tamsulosin) and increasing research and development expenses to cultivate new products
You may also be interested in...
Astellas Takes First Steps In India With Prograf
TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country
Astellas Takes First Steps In India With Prograf
TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country
Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference
TOKYO - Astellas, like most top-tier Japanese pharmaceutical companies, has been aggressive in its out-licensing in the past year, and its 2009 joint venture with Maxygen highlights how Japanese companies are using creative deals to stay competitive